Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
Upon binding to the receptors, cascades of tyrosine and serine kinases are stimulated to facilitate growth or metabolism
Heavy-metal panels do not measure the fat-soluble persistent organic pollutants discussed in weight-loss studies and should not be presented as routine tests for toxins released from fat. Can rapid weight loss cause nutrient deficiencies
This eco-friendly ingredient boosts skin resilience and overall vitality
The liposome delivery vehicle creates a protective barrier around the glutathione molecules, so they survive the digestive tract in the preferable reduced state
Get Started Embarking on a weight loss program with Klinic is straightforward, particularly for residents of Vista, California
